We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hemoperfusion Helps Improve Outcomes for Patients with Severe Sepsis

By HospiMedica International staff writers
Posted on 30 Jun 2009
A new study has found that therapy for severe sepsis that includes the use of an antibiotic-based hemoperfusion device results in a reduced risk of death, improved blood circulation, and reduced organ dysfunction.

Researchers at St. More...
Bortolo Hospital and the International Renal Research Institute (Vicenza, Italy) conducted a randomized controlled trial in 64 patients with severe sepsis (or septic shock) who underwent emergency surgery for an intra-abdominal infection. The trial wished to determine whether conventional therapy with two supplementary sessions of polymyxin B hemoperfusion (34 patients) would improve clinical outcomes and survival, compared to conventional therapy alone (30 patients); the study was conducted at 10 Italian intensive care units (ICUs). The primary outcome was change in mean arterial pressure (MAP) and vasopressor requirement, and secondary outcomes were fraction of inspired oxygen ratio, change in organ dysfunction (measured using sequential organ failure assessment (SOFA) scores), and 28-day mortality.

The researchers found that polymyxin B hemoperfusion therapy was effective in improving 28-day mortality (32% percent) in the polymyxin B group, compared to 53% mortality in the conventional therapy group. MAP increased and vasopressor requirement decreased at 72 hours in the polymyxin B group, but not in the conventional therapy group. Additionally, the fraction of inspired oxygen ratio increased slightly in the polymyxin B group, but not in the conventional therapy group. The study was published in the June 17, 2009, issue of the Journal of the American Medical Association (JAMA).

"Polymyxin B hemoperfusion added to conventional therapy significantly improved hemodynamics and organ dysfunction and reduced 28-day mortality,” concluded lead author Dinna Cruz, M.D., M.P.H., and colleagues of the department of nephrology, dialysis, and transplantation. "We advocate further studies to explore the use of newer assays for endotoxin activity both for patient selection, as well as guiding the number of hemoperfusion sessions.”

Polymyxin B is a cationic antibiotic primarily used for resistant gram-negative infections, which works similarly to a detergent, by binding to the cell membrane and altering its structure. This makes the bacteria cell wall more permeable, resulting in water uptake into the bacteria, leading to cell death.

Related Links:
St. Bortolo Hospital and the International Renal Research Institute



Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Gas Analyzer
GE SAM
New
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.